title: [Biotherapy of malignant peritoneal effusions in ovarian carcinoma].
abstract: Malignant peritoneal effusions often arise in patients with ovarian carcinoma. They are a hazardous complication of cancer. Systematic intraperitoneal chemotherapy is not necessarily followed by long-term remission and may even induce untoward side effects. Intraperitoneal interleukin-2 (IL-2) and IL-2/lymphokine-activated killers (LAK) biotherapy showed high efficacy in treatment of ovarian carcinoma patients suffering from peritoneal effusions. The objective effect was 80.1% and 82.6%, respectively. Our results suggest that intraperitoneal biotherapy may be extended to dealing with malignant peritoneal effusions in ovarian carcinoma.
authors.forename: K S
authors.initials: KS
authors.lastname: Titov
authors.forename: A N
authors.initials: AN
authors.lastname: Gritsaĭ
authors.forename: M V
authors.initials: MV
authors.lastname: Kiselevskiĭ
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Sel'chuk
authors.forename: G V
authors.initials: GV
authors.lastname: Timova
authors.forename: E Kh
authors.initials: EKh
authors.lastname: Kuchmezov
authors.forename: A K
authors.initials: AK
authors.lastname: Antonov
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001202:Ascitic Fluid / Q000187:drug effects* / Q000473:pathology; D001691:Biological Therapy / Q000379:methods*; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007376:Interleukin-2 / Q000008:administration & dosage*; D015979:Killer Cells, Lymphokine-Activated; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2